Malaria Review: Info & Updates

Malaria Eradication Resourcs



A dynamic multimedia review of malaria is presented here. It combines images, diagrams, video links, slides and live feeds from WHO, CDC and updates from top biomedical journals. Malaria remains a major killer infecting 300-500 million persons each year and killing over 1 million patients. MMV estimates that every 30 seconds a child dies of malaria even though treatment is available and these untimely deaths can be prevented. The annual funding of $5 billion is required to make a significant impact on malaria deaths and cases. The actual funding in 2009 was only $1.5 billion barely about 30% of the requirement . World malaria day 2011, major progress made in Africa, newcases and deaths reduced by over 50% in 11 countries. The GSK malaria vaccine shows efficacy in a major global trial. Still around 3.3 billion persons remain at risk and 225 million cases were reported to the WHO in 2009 with 781000 deaths. The malaria related mortality rates declined by 25% during the last decade and by 33% in the endemic African countries. This was due to better malaria resources mobilization, prevention and control measures like bed nets, rapid diagnostic tests and low cost medicines to treat malaria. The current economic difficulties and emergence of drug and insecticide resistance poses significant challenges. Registered & Protected

This website is certified by Health On the Net Foundation. Click to verify.This site complies with the HONcode standard for trustworthy health information: 
verify here.

Search only trustworthy HONcode health websites:

QR Code for smartphones and mobile devices

QR code

Short URL:

Publishers, corporations, educational, academic, government, foundations, organizations and readers are invited to read the following document for funding, sponsorship and commercial license opportunities.  

The document explains author’s policy: to provide trustworthy information, conflict of interest, marketplace and privacy and data protection issues. 




Image CDC PHIL 10924
 malaria life cycle

Version:1.0 StartHTML:0000000166 EndHTML:0000018057 StartFragment:0000002613 EndFragment:0000018021 SourceURL:file://localhost/Users/krohde/Desktop/Malaria.doc

Wellcome Trust Images


Agents and life cycle

Malaria (Italian “bad air”) is a disease caused by protistan (unicellular) parasites belonging to the Apicomplexa (sporozoans), genus Plasmodium. Many species are known which are specific to various reptiles, birds and mammals [1] [2] [3]. Human malaria is caused by four species, Plasmodium falciparum, P. vivax, P. malariae and (less commonly) P. ovale. The species P. knowlesi and P. cynomolgi, normally infecting macaque (and the second species also other) monkeys in Asia, rarely infect humans. The parasites have an indirect life cycle, i.e. they require two hosts. The intermediate host (humans), harbours sexually immature stages, the final host (in human malaria many mosquito species of the genus Anopheles) harbours sexually mature stages.

Mosquitoes inject malaria sporozoites into the bloodstream of humans when sucking blood. These stages penetrate into cells of the liver parenchyma, where they grow up to large cells, so-called megaschizonts (although some sporozoites of P.vivax and P.ovale may survive as “sleeping stages” (= hypnozoites) for long periods in the blood plasma before infecting host cells). After a number of days these stages multiply by asexual fission (= preerythrocytic or exoerythrocytic schizogony) giving rise to small merozoites, which are released into the bloodstream to infect erythrocytes(= red blood cells). They are now referred to as trophozoites (= feeding stages). They grow up to schizonts smaller than those in the liver, which again multiply by asexual fission (= erythrocytic schizogony), producing several to many (depending on the species) daughter cells, the merozoites. Host cells are destroyed during schizogony, their toxic substances released into the blood. Importantly, schizogony in the infected blood cells is synchronized, i.e. toxic substances from many destroyed cells are released at more or less the same time, leading to the malaria symptoms (chills, fever attacks, severe  headache, etc.). Merozoites infect other erythrocytes and the process of asexual reproduction is repeated many times. At a later stage, some of the merozoites are not transformed into feeding stages and schizonts, but into sexual cells (= male and female gametocytes). These circulate in the blood, where they cannot develop further until ingested by an Anopheles-mosquito. In the digestive tract of the mosquito, male gametocytes give rise to several male gametes by a process called  exflagellation (many flagella-like gametes arranged around a central residual body), whereas the female gametocyte is transformed into a single female gamete. One male gamete penetrates into a female one and fertilizes it forming a zygote which is mobile and therefore called an ookinete. It penetrates into the wall of the mosquito’e digestive tract and surrounds itself with a cyst wall, thus becoming an oocyst, containing a large number of sporozoites. After some time, the cyst wall of the oocyst raptures, releasing numerous sporozoites into the body cavity, from where they migrate mainly into the salivary glands of the mosquito. They enter the bloodstream of humans when they are injected by the mosquito.

The four major human species of malaria differ in morphology and symptoms produced, but in all species the first disease symptoms occur only once schizogonies in the blood have produced large numbers of merozoites infecting erythrocytes with subsequent breakup of large numbers of blood cells leading to the release of large quantities of toxic substances. In other words, no symptoms can be expected as long as infection is restricted to the liver, and during the early stages of the erythrocytic cycle. Depending on the malaria species and the health condition of the infected person, this prepatent period (= period without symptoms) can last a number of days or even several months.


Diagnosis of malaria is usually by examination of thin blood smears and thick blood films. Although live parasites are visible in fresh blood under the microscope, diagnosis relies on stained films and smears which permits not only the recognition of an infection but also the distinction of the different malaria species. This is important, because disease symptoms and prognosis depend on the species.

Plasmodium falciparum, thin blood smear showing trophozoites (ring stages) in the erythrocytes, and gametocytes. Note: some erythrocytes with two trophozoites, and the high proportion of infected erythrocytes. From CDC PHIL 2704

Plasmodium vivax, thin blood smear showing large trophozoite in an erythrocyte. Note the numerous pigment dots in the infected erythrocyte (= Schüffner’s dots) characteristic of P. vivax and P.ovale infections. From CDC PHIL 5863

Plasmodium malariae, thin blood smear showing schizont. From CDC PHIL 2715

Plasmodium ovale, thin blood film showing trophozoite (ring stage) in an erythrocyte. Note the fine dots (= Schüffner’s dots) in the infected erythrocyte. From CDC PHIL 2716


Most dangerous is Plasmodium falciparum which causes “tropica” and often “cerebral” or “pernicious” malaria, and frequently leads to death. However, other species also cause serious symptoms and sometimes death, although the vast majority of fatal cases are due to P. falciparum.

Symptoms of malaria caused by the various parasites include periodic fever and chill attacks (P. falciparum: every third day or even every day; P. vivax and ovale: every third day = “tertian” malaria; P. malariae: every fourth day = “quartan” malaria). Other symptoms include severe headache, joint pains, nausea, haemoglobin in the urine, and retinal damage. In P. falciparum, blackwater fever (large quantities of haemoglobin in the urine), enlarged spleen and renal failure are not uncommon.

File:Symptoms of Malaria.png

Symptoms may disappear after a while, usually due to treatment, but relapses (= re-occurrences of attacks) are possible, often after many years.


The vector

Vectors of human malaria all belong to the genus Anopheles which require water bodies (stagnant pools, creeks, rivers, small water bodies on epiphytes, etc., depending on the species) for completion of their life cycle. Species of this genus can be distinguished from other mosquito genera by a number of characters, among them the following: eggs with air sacs or floats are laid singly (and not in rafts) in water, larvae lie parallel to the surface film in water when breathing or feeding, breathing tubes of pupae are short and broad at margin, and adults of most species rest with the proboscis in a straight line with the body. – Only female Anopheles feed on blood and transmit malaria; males feed on plant juices.


CDC PHIL ID 7862   Anopheles albimanus, a malaria mosquito feeding on a human.

Experiments have shown that many species of Anopheles can be infected with species of human Plasmodium. However, in nature it is usually a single species or very few that transmit the disease in a particular geographical area. Since each species has different ecological requirements, particularly for breeding, eradication programs for malaria require detailed studies of the ecology of the vectors in each area, which in turn necessitates a detailed knowledge of the morphology and life cycle of the species involved.


Anopheles minimus, a malaria vector feeding on a human host 

Intra-uterine infections

In some instances, the new-born baby may develop malaria symptoms as the result of infections acquired from the mother as a foetus. Also, very rarely blood transfusions or sharing of needles may transmit the parasite.


Malaria control                       

The fight against malaria has been fought on several fronts: 1) Prevention of infection by using mosquito nets and insect repellents.2) Mosquito eradication using insecticides (which sometimes have severe environmental impacts), combined with detailed ecological studies to permit the correct application of insecticides. 3) Prophylactic drugs, and drugs used for treatment like quinine, chloroquine, arteminisin, atebrin etc. etc., to which – however – resistance developed and is developing fairly fast, so that new medications have to be developed continually. 4) Development of vaccines. To date, projects to develop vaccines against malaria have been successful only to a marginal degree. No vaccine exists that protects the majority of people against several strains of even one species of malaria.

Geographical distribution of malaria

Human malaria is not restricted to tropical/subtropical regions, but has occurred – in history – at high northern and southern latitudes. For example, is was not rare in the Netherlands and northern Russia, although never as common as at low latitudes. Due to effective eradication programs, it is now almost exclusively found in tropical/subtropical regions.

 CDC travel Advisory and Global Malaria Risk Map


 Wellcome Trust 2007 Malaria Map

Organizations Involved in Global Eradication of Malaria
Too many players on the same target, yet lack of resources.
Different priorities, agendas resulting in wasted efforts to resolve donor differences
Resources wasted on meetings, travel, glossy printouts and reports
Market success missing as a driving factor
Measurable targets not well defined
Projects with low probability of success rarely terminated
Lessons learned from past failures rarely factored in current campaigns

Need a single United Nations of Malaria


Fig 1     Global Malaria Eradication 2009



 [MMV]Malaria Vaccine Initiative






 The Global Fund logo










UN Special Envoy for Malaria, UNDP, UNICEF


GSK, WEF, Boston Consulting Group, MacroInternational, Carter Center, DFID


Universities: Columbia, London School of Tropical Medicine, Johns Hopkins, Imperial College, Harvard, Swiss Institute of Tropical Medicine,

Africa Fighting Malaria, Artimisin and Farming international, Fogarty International Center, Global Health Council, Foundation for Innovative New Diagnosis, Innovative Vector Control, Intelligent Insect Control, Development Finance International

Under Creative Commons Attribution 3.0 License

 The Limits and Intensity of Plasmodium falciparum Transmission: Implications for Malaria Control and Elimination Worldwide
Carlos A. Guerra, Priscilla W. Gikandi, Andrew J. Tatem, Abdisalan M. Noor, Dave L. Smith, Simon I. Hay, Robert W. Snow
PLoS Med 5(2): e38
 Figure 1. P. falciparum Malaria Risk Defined by Annual Parasite Incidence (top), Temperature, and Aridity (bottom)

Areas were defined as stable (dark-red areas, where PfAPI ≥ 0.1 per thousand pa), unstable (pink areas, where PfAPI < 0.1 per thousand pa), or no risk (light grey). The few areas for which no PfAPI data could be obtained, mainly found in India, are coloured in dark grey. The borders of the 87 countries defined as P. falciparum endemic are shown. Highland areas where risk was excluded due to temperature appear in light grey. The aridity mask excluded risk in a step-wise fashion, reflected mainly in the larger extents of unstable (pink) areas compared to the top panel, particularly in the Sahel and southwest Asia (southern Iran and Pakistan).


 YouTube Video


WHO was the first international body to focus on diseases and health problems of developing countries. The early years were the period of new drug discoveries, antibiotics and the donor nations of the West and WHO. It was assumed that they had the means and drugs in hand to eradicate most of the tropical disease like malaria and TB. Most of these top driven early efforts ordered by donor countries of the West failed. The Rockefeller Foundation had funded and started the first global campaign to eradicate malaria by spraying of insecticide DDT and bednets to keep mosquitos out. The programme was successful in some European countries. The impact in developing countries was mixed. The newly formed WHO promptly adopted the malaria eradication as its top priority in early 1960s. The eradication campaign ran for almost 15 years and was a failure in most developing countries. The concerns about the evironmental impact of widespread use of chlorinated pesticides and the high cost(almost 30% of WHO budget) with poor results led to the demise of the second global malaria eradication project.  




World Health Organization

By mid 1970s units were formed within WHO to deal with Tropical Disease Research (TDR) , Vaccines and Child and Maternal Health. TDR initiated and started global efforts to eradicate and eliminate malaria, smallpox and tuberculosis without local input or involvement. Lack of funds and the use of low cost drug treatment led once again to failure of such campaigns and development of drug resistance. Although choroquine had become ineffective (drug resistance) it was used until 2001 because it was cheap and alternatives were  more expensive. Use of artimisinin was recommended in 2001, it costs more and requires monitoring for cardiotoxicity. Ridley and Fletcher have discussed the history and achievements of TDR and how to deal with future challenges (  TDR timelines of key achievements is available at

The global burden of disease, malaria and TB prevalence and distribution is available at


. WHO Data and map :


Map 2. Global distribution of dominant malaria vectors, 2003 ( 75) 

Source  WHO Roll Back Malaria :

File:Paludisme - Frequence statistique.png


The Global Fund to fight AIDS, Tuberculosis and Malaria (( under UN system in Geneva, has spent millions to provide nets, insecticides and malaria treatments in poor and developing countries.

 The Global Fund to Fight AIDS, Tuberculosis and Malaria

The MMV was the first PPP formed in 1999 and since then has developed an R&D portfolio of over 60 projects. MMV was founded by WHO, International Federation of Pharmaceutical Manufacturers Association, IFPMA, Global Forum for Health GFHR, Rockefeller Foundation, The World Bank, ABPI, The Wellcome Trust and Swiss Agency for Development.


YouTube Video


A selection of pages within the site most relevant to the media:

17 October 2011 — An updated WHO factsheet shows that there were 225 million cases of malaria and an estimated 781 000 deaths in 2009, a decrease from 233 million cases and 985 000 deaths in 2000.

-  MMV at a Glance – a brochure about MMV
Download MMV at a Glance (High Resolution PDF) (4MB)
Download MMV at a Glance (Low Resolution PDF) (1MB)

-  MMV en français – guide des pages MMV en français

Malaria Program Providing Spectacular Global Results 

Medical News Today - ‎24 minutes ago‎

The huge increase in malaria control programs since 2008 is starting to provide impressive results, says WHO (World Health Organization).

Malaria control ‘best in decades’: WHO

WHO Director Calls Malaria Rates ‘Best’ in Decades MedPage Today

Source: World Health Organization

“World Malaria Report 2010”

-  MMV in Natural Products (PDF format, 1.8MB)
June 2009

The essential reference for malaria control programmes around the world

March 2010

co-authored by Dr Timothy N.C. Wells, Dr Jeremy N. Burrows and Dr J. Kevin Baird

February 2010

Article by Tim Wells in Preclinical Drug Development

Discovering New Medicines to Control and Eradicate Malaria

A book chapter authored by Jeremy Burrows and David Waterson

September 2011

World Malaria Report 2011
The malaria related mortality rates declined by 25% during the last decade and by 33% in the endemic African countries. This was due to better malaria resources mobilization, prevention and control measures like bed nets, rapid diagnostic tests and low cost medicines to treat malaria. The current economic difficulties and emergence of drug and insecticide resistance poses significant challenges. There were 216 million cases in 106 countries and 655000 deaths in 2010. About 80% of cases and 91% of deaths were in Africa and 86% of victims were children under 5 years of age.

Interactive science portfolio

MMV’s portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Specifically, the goal is to develop products that will provide: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnancy), safety in small children (less than 6 months old), safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking treatment.

The MMV project portfolio is updated quarterly. Click on a project below for more information.

For more information about the global malaria portfolio, read the article: The Global Portfolio of New Antimalarial Medicines Under Development.

MP – miniportfolio: MMV pioneered the miniportfolio model. The model assures flexibility in allocation of resources – established between MMV and a Pharmaceutical or Biotechnology partner – from one project to another. In this way, resources are utilized as efficiently as possible.

December 2009


Andrew Witty announces ‘open innovation’ strategy focusing on neglected diseases and malaria

 Malaria Vaccine Initiative

The development of vaccine for malaria led to the formation of MVI by PATH. Malaria kills over 1 million patients each year and infects over 300-500 million persons resulting in a $12 billion loss of productivity in Afrian countries. The disease can be prevented, diagnosed rapidly and treated by insecticides spays to control mosquitos, bednets to prevent mosquito biting human victims and rapid field test for Plasmodium falciparum infections. The cheap drugs chloroquine/sulphadoxine are not effective due to drug resistance and artimisin based treatment costs much more and requires monitoring. Phase III trials with vaccine show only 30% efficacy (only 1 out of 3 person is protected by the vaccine). such a vaccine if approved can still save over 300,000 deaths each year at relativly low cost and simple treatment. there are 16 malaria vaccines in clinical trials.

MVI portfolio, September 2011

First results from ongoing Phase III trial show GSK malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African children aged 5 to 17 months

Issued: Tuesday 18 October 2011, London UK

Half the world’s population is at risk of malaria which is responsible for close to 800,000 deaths each year, most of whom are children under five in sub-Saharan Africa

First results from a large-scale Phase III trial of RTS,S, published online today in theNew England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced today at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, Washington. 

Malaria’s weak spot pinpointed in the hunt for an effective vaccine‎ The Guardian

NEJM October 18, 2011 | The RTS,S Clinical Trials Partnership
(DOI: 10.1056/NEJMoa1102287)


YouTube Video

Graphic showing 4 shaded ovals in flower formation: antigens, platforms, evaluation technologies, and adjuvants/formulations. The ovals overlap in the center of the graphic. The area of overlap is labeled, "at least 80% efficacious vaccine."

Graphic showing portfolio of vaccine candidates and research programs. Includes three types of vaccines: adjuvanted recombinant proteins, viral vectored, and live attenuated. Shows where each candidate or research program is in development pipeline, beginning with "construct selection" and ending with Phase 3. The most advanced candidate is GSK RTS,S AS01/02, currently in Phase 2B.

At the end of World war II, the disease was endemic all over the world, it has now been eradicated in most of the Western World and over 100 countries. Development of resistance to insecticides, environmental concerns, lack of funds, political will for sustained campaign, high cost of artimisin based treatment regiment and long duration of treatment have derailed several past and current eradication campaigns.  


Malaria Vaccine Initiative (MVI). (

Medicine for Malaria Venture (
The price of artemisinin has ranged from $ 150-1200/kg during the past decade with current prices around $ 400/Kg. 

  World Bank                                     

Foundation for Innovative New Diagnostics
For evaluation of and new rapid diagnostic tests


Program for Appropriate Technology in Health

The main objective is to adopt Western developed technolgy and health solution to local conditions in poor countries and make it suitable for use by local communities.

Bill & Melinda Gates Foundation

We Can End Malaria
Learn about the number of lives saved, and more.


William J. Clinton Foundation

Drugs for Neglected Diseases Initiative (

The award of the Nobel peace prize to Medicine Sans Frontier (Doctors without borders, MSF) led to the formation of this virtual PPP. The high human cost of the neglected diseases (Trypanosomiasis or sleeping sickness, Leishmaniasis, Chagas Disease and Malaria) is due to lack of new drugs to treat patients.

Médecins Sans Frontières MSF, Institut Pasteur, Indian Council of Medical Research,

Oswaldo Cruz Foundation (FIOCRUZ),  TDR, and Health Ministry in Malaysia joined to develop new drugs. There were 21 projects in the R&D portfolio of DNDI.



New medicines to improve control and contribute to the eradication of malaria

Timothy N. C. Wells, Pedro L. Alonso & Winston E. Gutteridge

Nature Reviews Drug Discovery 8, 879-891 (November 2009) | doi:10.1038/nrd2972


The persistent threat of resistance means that new molecules with novel mechanisms of action are continually required. Furthermore, the recent call for the elimination and eradication of malaria has prompted an extension of the stages of the life cycle of malaria parasites that should be targeted by new molecules. Recent advances in genome-based technologies and in in vitro screening of whole parasites have broadened the range of therapeutic targets and are accelerating the development of a new generation of treatments for both malaria control and eradication.

11 October 2011

With funding from European Union under Framework Seven, a Consortium of 10 organisations, CRIMALDDI*, has developed an integrated and prioritised 5-year Roadmap for antimalarial drug discovery. This is to guide donors, policy makers, and researchers. The Roadmap will be launched today, at the meeting of the All-Party Parliamentary Group on Malaria and Neglected Tropical Diseases (APPMG) in Westminster. It will help to design the European antimalarial research agenda for the next decade as well as contribute to the setting of global priorities.

Famous Victims 

Alexander the Great
Genghis Khan
King Edward IV
Several Popes
Oliver Cromwell
Lord Byron

Hawass, Z; Gad, ZY; Ismail, S; Khairat, R; Fathalla, D; Hasan, N; Ahmed,A;Elleithy, H; Ball, M; Gaballah, F; Wasef, S; Fateen, M; Amer, H; Gostner, P; Selim, A; Albert Zink, A; Pusch, CM. Ancestry and Pathology in King Tutankhamun’s Family. JAMA. 2010;303(7):638-647.

Image from Wikipedia

Malaria Patients

George Washington
Abraham Lincoln
Theodor Roosevelt
John F Keneddy
Christopher Columbus
Jesse James
Lord Nelson
Artur Conan Doyle
Ernest Hemingway
M K Gandhi
Ho Chi Minh
Leon Trotsky

Nobel Prize for Malaria

1902  Ronald Ross
1907  Lavaren
1948  Muller 

Books and Monographs                                                                                                                

PLoS Collection Malaria

malERA – a research agenda for malaria eradication

The Malaria Eradication Research Agenda (malERA) initiative complements existing research agendas, which are primarily aimed at reducing the global burden of morbidity and mortality due to malaria by malaria control, with a set of research and development priorities that identify knowledge gaps and tools needed for worldwide eradication of malaria. Over the course of two years, more than 250 experts from 36 countries participated in 20 malERA meetings around the world, producing a draft research and development agenda that was refined during the malERA “Zenith Week” meeting in Washington D.C., in March, 2010. This sponsored Collection of 12 Reviews comprises three reflective pieces and nine research and development agendas that arose from these consultations.

Produced with support from the Malaria Eradication Research Agenda (malERA) initiative, which was funded by a grant from the Bill & Melinda Gates Foundation. The PLoS Medicine editors have sole editorial responsibility for the content of this collection.

Download: Complete Collection (3.8 MB PDF).

Reviews Top

Pedro L. Alonso, Graham Brown, Myriam Arevalo-Herrera, Fred Binka, Chetan Chitnis, Frank Collins, Ogobara K. Doumbo, Brian Greenwood, B. Fenton Hall, Myron M. Levine, Kamini Mendis, Robert D. Newman, Christopher V. Plowe, Mario Henry Rodríguez, Robert Sinden, Laurence Slutsker, Marcel Tanner

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000406

The malERA Consultative Group on Basic Science and Enabling Technologies

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000399

The malERA Consultative Group on Drugs

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000402

Box 2. A Draft Research and Development Agenda for Drugs for Malaria Eradication


  • Pharmacology studies to optimize dosing regimens of 8-aminoquinolines for gametocytocidal and anti-relapse efficacy and safety
  • Rapid and robust point-of-care glucose-6-phosphate dehydrogenase (G6PD) test to improve safety of 8-aminoquinoline use
  • Tests that can detect resistance to artemisinins and ACT partner drugs
  • Determine gametocytocidal and anti-relapse activity of current drugs and those in the pipeline


Desired products

  • Drugs that prevent transmission by killing or preventing development of gametocytes, or blocking sporozoite development in the mosquito
  • Drugs that cure liver stages of vivax (and ovale) malaria
  • Ideally, drugs that can be administered in a single encounter at infrequent intervals, and that result in radical cure of all parasite stages (Single Encounter Radical Cure and Prophylaxis, seeBox 1)
  • Sustained or pulsed release formulations
  • Exceptionally safe schizonticidal drugs for curing asymptomatic falciparum infection

Fundamental research questions aimed towards developing desired drugs

  • Fundamental studies of liver and sexual stage biology (in both host and mosquito)
  • Mechanisms of resistance and pharmacological strategies to deter resistance
  • In vitro culture of P. vivax to understand parasite biology

Tools and capacities

  • Increased capacity for clinical pharmacology research including pharmacokinetics/pharmacodynamics studies in populations targeted for malaria elimination
  • Increased capacity for human challenge studies for early go/no go decisions on drug candidates
  • Assays to measure transmission-blocking activity
  • Assays to measure activity against liver stages
  • In vitro culture of P. vivax and other non-falciparum species for drug screening
  • Genomic and proteomic approaches to identify transmission-blocking and liver-stage activity


  • Field studies to evaluate new drugs and approaches in a variety of epidemiological settings
  • Robust and highly sensitive malaria diagnostics for malaria infection and especially for carriage of infectious gametocytes
  • Measures to monitor and improve adherence and safety
  • How must drug treatment and prevention strategies change as elimination proceeds?
  • Strategies to deter resistance

The malERA Consultative Group on Vaccines

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000398

Summary Points

  • Vaccines for malaria eradication need to have an impact on transmission rather than focusing on mortality and morbidity reduction alone
  • Vaccines that interrupt malaria transmission (VIMT) may target many stages of the parasite’s life cycle, not just the sexual and mosquito stages as in classical blocking vaccines and multiple plasmodium species, in particular Plasmodium vivax
  • Novel vaccine delivery approaches and adjuvants need to be developed
  • Other priority areas for research and development include the development of tools to measure transmission rates and the development of robust assays of functional immune responses in individuals, which could inform vaccine development
  • A better understanding of the dynamics between the multiplication of parasites, gametocytogenesis, and malaria transmission rates in populations is also needed

The malERA Consultative Group on Vector Control

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000401

The malERA Consultative Group on Diagnoses and Diagnostics

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000396

Summary Points

  • New and improved screening tools and strategies are required for detection and management of very low-density parasitemia in the field
  • Improved quality control is required for rapid diagnostic tests (RDTs) and microscopy in the field, to ensure confidence in diagnosis for case management
  • More sensitive tests are required for Plasmodium vivax for case management
  • Field-ready glucose-6-phosphate dehydrogenase (G6PD) deficiency tests and strategies for use to allow safe use of drugs against P. vivax liver stages are needed
  • New strategies to manage parasite-negative individuals are needed to justify the continued inclusion of malaria diagnostics in febrile disease management in very low transmission areas.

The malERA Consultative Group on Health Systems and Operational Research

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000397

The malERA Consultative Group on Monitoring, Evaluation, and Surveillance

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000400

The malERA Consultative Group on Modeling

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000403

The malERA Consultative Group on Integration Strategies

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000404

José A. Nájera, Matiana González-Silva, Pedro L. Alonso

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000412

Joel G. Breman, Ciro A. de Quadros, Walter R. Dowdle, William H. Foege, Donald A. Henderson, T. Jacob John, Myron M. Levine

PLoS Medicine:
Published 25 Jan 2011 | info:doi/10.1371/journal.pmed.1000405

World Malaria Day - April 25th 2011


Fighting Malaria: Will US Cuts Hurt Global Effort? 

NPR - ‎15 hours ago‎

On this World Malaria Day, African countries celebrate major gains in fighting malaria. During the past 10 years, 11 African countries have seen new malaria cases and deaths drop by more than 50 percent – due in large part to funding by international 

UN: efforts on track to halt malaria deaths The Associated Press


WHO Launches Attack on Emerging Malaria Resistance

Science AAAS - Martin Enserink - ‎5 hours ago‎

The World Health Organization (WHO) released a plan today to deal with a threat that could undermine the recent success in malaria control: the emerging resistance against 

Drug-resistant malaria could spread fast, expert warns 

Reuters - Joseph Okanga - ‎9 hours ago‎

A child is given an injection as part of a malaria vaccine trial at a clinic in the Kenya coastal town of Kilifi, KenyaNovember 23, 2010.

Health Highlights: Jan. 12, 2011 BusinessWeek

UN health agency launches action plan to halt malaria drug resistance UN News Centre



Thanks are due to Mr. Jean-Antoine de Mandato (PDP, Geneva) for providing office facilities and administrative support.
Authors and Knols

Klaus Rohde

Klaus Rohde knols English

My bio


Patrick Lahaye

Patrick LAHAYE’s Knols, tutorials and videos Knols (English)

Mark it as your favorite knol      Favorite

Share and Communicate                                                                                                            

shareSocial Bookmarking





  • Kreier,J.P. and Baker,J.R. (1987). Parasitic Protozoa. Allen & Unwin, Boston.
  • Bogitsh, B.J. and Cheng, T.C. (1999). Human Parasitology. 2nd edition Academic Press, San Diego.
  • Schmidt G.D., Roberts L.S. & Janovy, J. (1995). Foundations of Parasitology. 5th Edition McGraw Hill, New York.